In addition, immune checkpoint inhibitors with nivolumab- (anti-programmed cell death-1 mAb) and ipilimumab- (anti-cytotoxic T lymphocyte antigen-4 mAb) induced CRS were also reported in 2021, in which CRP, aspartate aminotransferase, alanine aminotransaminase, and D-dimer were significantly increased after nivolumab and ipilimumab infusion.62 At last, other mAbs63–66 most commonly associated with CRS are also listed in Table 3. This evidence concerns the gene CRP and congenital rubella syndrome.